Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
Abdelmagid MG, Al-Kali A, Litzow MR, Begna KH, Hogan WJ, Patnaik MS, Hashmi SK, Elliott MA, Alkhateeb H, Karrar OS, Fleti F, Elnayir MH, Rivera CE, Murthy HS, Foran JM, Kharfan-Dabaja MA, Badar T, Viswanatha DS, Reichard KK, Gangat N, Tefferi A. Abdelmagid MG, et al. Blood Cancer J. 2023 Aug 11;13(1):122. doi: 10.1038/s41408-023-00891-x. Blood Cancer J. 2023. PMID: 37567878 Free PMC article.
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting.
Singh A, Al-Kali A, Foran JM, Elliott MA, Begna K, Badar T, Khera N, Fleti F, Abdelmagid M, Reichard KK, Ketterling RP, Pardanani A, Gangat N, Tefferi A. Singh A, et al. Am J Hematol. 2022 Oct;97(10):E377-E379. doi: 10.1002/ajh.26672. Epub 2022 Aug 12. Am J Hematol. 2022. PMID: 35959963 Free article. No abstract available.
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases.
Fleti F, Chan O, Singh A, Abdelmagid MG, Al-Kali A, Elliott MA, Begna KH, Foran JM, Badar T, Khera N, Al Ali NH, Padron E, Sallman DA, Shah M, Hiwase D, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R, Tefferi A. Fleti F, et al. Among authors: abdelmagid mg. Am J Hematol. 2023 Apr;98(4):E76-E79. doi: 10.1002/ajh.26845. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36655582 Free article. No abstract available.
Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival.
Gangat N, Kuykendall A, Al Ali N, Goel S, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Komrokji R, Tefferi A. Gangat N, et al. Blood Adv. 2023 Jun 27;7(12):2694-2698. doi: 10.1182/bloodadvances.2022009611. Blood Adv. 2023. PMID: 36780345 Free PMC article. No abstract available.
Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival.
Abdelmagid MG, Al-Kali A, Begna KH, Hogan WJ, Litzow MR, Fleti F, Mangaonkar AA, Patnaik MS, Elliott MA, Alkhateeb H, Shi M, Howard MT, Reichard KK, Ketterling RP, Shah M, Pardanani A, Gangat N, Tefferi A. Abdelmagid MG, et al. Haematologica. 2023 Sep 1;108(9):2542-2545. doi: 10.3324/haematol.2022.282627. Haematologica. 2023. PMID: 36794509 Free PMC article. No abstract available.
Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia.
Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Gangat N, et al. Haematologica. 2024 Jan 1;109(1):187-292. doi: 10.3324/haematol.2023.283732. Haematologica. 2024. PMID: 37534525 Free PMC article. No abstract available.
22 results